GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Shineway Pharmaceutical Group Ltd (OTCPK:CSWYF) » Definitions » EBIT

China Shineway Pharmaceutical Group (China Shineway Pharmaceutical Group) EBIT : $173.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is China Shineway Pharmaceutical Group EBIT?

China Shineway Pharmaceutical Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $80.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $173.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China Shineway Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2023 was 26.90%. China Shineway Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 93.65%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China Shineway Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 85.39%.


China Shineway Pharmaceutical Group EBIT Historical Data

The historical data trend for China Shineway Pharmaceutical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Shineway Pharmaceutical Group EBIT Chart

China Shineway Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.02 62.95 113.26 131.63 174.08

China Shineway Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.32 61.50 72.57 93.76 80.04

Competitive Comparison of China Shineway Pharmaceutical Group's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Shineway Pharmaceutical Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's EV-to-EBIT falls into.



China Shineway Pharmaceutical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $173.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Shineway Pharmaceutical Group  (OTCPK:CSWYF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China Shineway Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=107.362 * ( 1 - 15.98% )/( (257.607 + 413.03)/ 2 )
=90.2055524/335.3185
=26.90 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1243.11 - 236.431 - ( 749.096 - max(0, 289.978 - 1039.05+749.096))
=257.607

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1340.858 - 126.588 - ( 827.536 - max(0, 340.847 - 1142.087+827.536))
=413.03

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

China Shineway Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=160.088/( ( (173.082 + max(-29.941, 0)) + (168.803 + max(-63.52, 0)) )/ 2 )
=160.088/( ( 173.082 + 168.803 )/ 2 )
=160.088/170.9425
=93.65 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(106.03 + 111.612 + 0) - (236.431 + 0 + 11.152)
=-29.941

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(106.188 + 125.726 + 3.261) - (126.588 + 0 + 172.107)
=-63.52

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China Shineway Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=173.805/203.543
=85.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Shineway Pharmaceutical Group EBIT Related Terms

Thank you for viewing the detailed overview of China Shineway Pharmaceutical Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


China Shineway Pharmaceutical Group (China Shineway Pharmaceutical Group) Business Description

Traded in Other Exchanges
Address
Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company in the People's Republic of China. Principally, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, and others of which injection generates maximum revenue to the company.

China Shineway Pharmaceutical Group (China Shineway Pharmaceutical Group) Headlines